Zobrazeno 1 - 10
of 198
pro vyhledávání: ''
Autor:
Julie Means-Powell, Luis Del Valle, Vandana G. Abramson, Claudia Sorrentino, Melinda Sanders, Ingrid A. Mayer, Debra A. Tonetti, Roohi Ismail-Khan, Samarpan Majumder, Richard M Lush, Lucio Miele
Publikováno v:
Clin Breast Cancer
Preclinical studies have demonstrated a complex cross-talk between Notch and estrogen signaling in ERα-positive breast cancer. Gamma-secretase inhibitors (GSIs) are investigational agents that block the cleavage and activation of Notch receptors. In
Autor:
Ursa Brown-Glaberman, Hannah M. Linden, Lynn Symonds, Jennifer M. Specht, Eve T. Rodler, Isaac C. Jenkins, Xiaoyu Chai, Georgiana K. Ellis, Pavani Chalasani, Jinny Riedel, Brenda F. Kurland, Julie Gralow, Alison Stopeck, Qian Wu, Vijayakrishna V K Gadi
Publikováno v:
Clin Breast Cancer
INTRODUCTION Neoadjuvant chemotherapy is standard treatment for locally advanced (LABC) or inflammatory breast cancer (IBC). We hypothesized adding sunitinib, a tyrosine kinase inhibitor with anti-tumor and anti-angiogenic activity, to an anthracycli
Autor:
Gianluca Vullo, Mattia Falchetto Osti, Giovanna Gallo, Gerardo Salerno, Lucio Marinelli, Patrizia Cardelli, Maurizio Valeriani, Marco Alfò, Giovanna Scalabrino, Giuseppe Facondo, C. Vitiello, Ivana Russo, Barbara Campanella, Simone Burocchi, L. De Biase, V. De Sanctis
Publikováno v:
Clinical Breast Cancer. 21:e141-e149
Purpose To evaluate, in a series of early breast cancer (BC) patients treated with hypofractionated adjuvant radiotherapy (RT), whether N-terminal–pro hormone B-type natriuretic peptide (NT-proBNP) and high-sensitivity cardiac troponin I assay meas
Autor:
Margaret M. Kozak, Frederick M. Dirbas, Emily Walck, Rie von Eyben, Clare E. Jacobson, Kathleen C. Horst, Paulina M. Gutkin
Publikováno v:
Clinical Breast Cancer. 20:431-438
Background Optimal surgical management of limited axillary nodal disease following neoadjuvant chemotherapy (NAC) for breast cancer is evolving. Concerns exist with respect to leaving residual disease in the axilla when omitting axillary lymph node d
Autor:
Stephanie Dille, Richard A. Hansen, Johanna Harde, Karin Potthoff, Oliver Stötzer, Norbert Marschner, Ulrike Söling, Arnd Nusch
Publikováno v:
Clinical Breast Cancer. 20:e315-e326
Background There are only scarce data on treatment of elderly patients with nab-paclitaxel for metastatic breast cancer, especially from the real-world setting. Here we present data from the noninterventional study NABUCCO with special focus on taxan
Autor:
Zoé Guillaume, Jacques Medioni, Agnes Lillo-Lelouet, Stéphane Oudard, Audrey Simonaggio, Grégoire Marret
Publikováno v:
Clinical Breast Cancer. 20:e192-e195
Autor:
Eustratios Bananis, Miguel Martin, Richard S. Finn, Aurelio Castrellon, Anil Abraham Joy, Eric Gauthier, Hirofumi Mukai, Janice M. Walshe, Hope S. Rugo, A. Mori, D. Lu, Nadia Harbeck, Karen A. Gelmon, Véronique Diéras
Publikováno v:
Clinical Breast Cancer. 20:e173-e180
Background In PALOMA-2, palbociclib + letrozole significantly prolonged progression-free survival (PFS) versus placebo + letrozole in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER+/HER2−) advanced br
Autor:
Robert Wesolowski, Junan Li, Raquel E. Reinbolt, Bhuvaneswari Ramaswamy, Jonathan Wilkie, Craig A. Vargo, Sagar Sardesai, Anne M. Noonan, Michael Berger, M. Alexandra Schickli, Nicole Williams, Maryam B. Lustberg, Daniel G. Stover, Jeffrey VanDeusen
Publikováno v:
Clinical Breast Cancer. 20:33-40
Background Additional use of cyclin-dependent kinase 4/6 inhibitors with endocrine therapy improves progression-free survival (PFS) in advanced hormone receptor (HR)-positive HER2-negative breast cancer. However, neutropenia is a common reason for do
Publikováno v:
Clinical Breast Cancer. 20:e82-e88
Background Clinical response evaluation by image examination after neoadjuvant chemotherapy for breast cancer is important for determining drug response and progression. Mammography is less correlated with pathologic response assessment than magnetic
Autor:
Ritu Aneja, Zhimin Wei, Jane L. Meisel, Xiaoxian Li, Rita Nahta, Aili Suo, Chao Zhang, Ruth O'Regan, Jing Zhao, Caitlin E. Taylor, Zaibo Li, Uma Krishnamurti
Publikováno v:
Clinical Breast Cancer. 20:19-24
Background HER2-targeted neoadjuvant therapy has high efficacy in treating HER2-positive breast cancer. Response to neoadjuvant therapy helps clinicians make treatment decisions and make estimates about prognosis. This study examined clinicopathologi